Where does Pharma Consult GES.M.B.H. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pharma Consult GES.M.B.H. ranks #42,319 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pharma Consult GES.M.B.H. hold?

Pharma Consult GES.M.B.H. holds 6 US utility patents granted between 2016 and 2023, spanning 1 technology areas.

What is Pharma Consult GES.M.B.H.'s Innovation Score?

Pharma Consult GES.M.B.H. has an Innovation Score of 27.1 out of 100 (23rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Pharma Consult GES.M.B.H.'s patent grant rate increasing or decreasing?

Pharma Consult GES.M.B.H.'s recent grant velocity is +100% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Pharma Consult GES.M.B.H.'s patents?

Pharma Consult GES.M.B.H.'s patents average 17.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pharma Consult GES.M.B.H. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Pharma Consult GES.M.B.H.

Q: What technology areas does Pharma Consult GES.M.B.H. focus on?

Pharma Consult GES.M.B.H.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 6 patents, ranking #1,115 of 3,490 assignees active in that subclass. Grants appear in 1 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 1 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pharma ranks #42,319 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 1 technology areas.

#42,319
of 49,997 US assignees by volume: 23rd percentile
by Innovation Score (27.1/100): 17.0
avg claims per patent: +100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R42319 · Foreign Corporation #42,319 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #42,319/49,997
PHOTO-FINISH Petelka Investments
CPC-NARROW A61M · 1 areas
INNOV-THIN 27.1/100
CLAIMS-RICH 17.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Petelka Investments Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Pharma’s 27.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (25%) Velocity 6.7 pts (25%) Breadth 3.5 pts (13%) Claim depth 10.2 pts (38%)

Qualcomm Incorporated · highest

85
Pharma Consult GES… · this assignee

27
3D Lighting… · lowest

7

What this shows Pharma's Innovation Score is 27.1/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Pharma?

Each dot is one of Pharma’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pharma’s own 17.0 claims/patent is ABOVE the 16.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Pharma vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Pharma's grants concentrate

Pharma Consult GES.M.B.H. is a focused PatentsView assignee: 1 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2016. By volume, Pharma sits between Petelka Investments Inc. and Phonoflow Medical LLC.

Pharma's three-year grant acceleration

Pharma Consult GES.M.B.H. shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Petelka Investmen…

6
PGP Glass USA

6
PHA

6
Phanto

6
Phase Change Soft…

6
Phenix Systems

6
Phoenix Neutron I…

6
Phonoflow Medical

6
Pharma Consult GE… ◀

6

What this shows Pharma holds 6 patents at rank #42,234, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pharma

By rank, the assignees closest to #42,234 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Pharma's primary technology class.

Pharma's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Pharma Consult GES.M.B.H. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	16.7%
2018	1	16.7%
2020	2	33.3%
2023	2	33.3%

Which technologies does Pharma Consult GES.M.B.H. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 6

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Pharma Consult GES.M.B.H.'s patent record in context - here's where to go next.

Pharma Consult GES.M.B.H.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #42,319 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pharma Consult GES.M.B.H. against Petelka Investments Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.